US court grants Sanofi-Aventis/Albany's injunction in generic Allegra case
This article was originally published in Scrip
Dr Reddy's Laboratories' stock lost some of its sheen in early trade on the Bombay Stock Exchange (BSE) on 14 June, after a US district court granted a preliminary injunction against the company's generic version of Sanofi-Aventis' anti-allergic, Allegra D24 (fexofenadine HCl/pseudoephedrine HCl 180mg/240mg extended release tablet).
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.